Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 zadavotide guraxetan

Next Previous
Drug Profile

Lutetium-177 zadavotide guraxetan

Alternative Names: 177-Lu PSMA imaging and therapy; 177-Lutetium-PSMA-I&T - Curium; 177Lu-PSMA-I&T; 177LU-PSMA-I&T; Lu-177-PSMA-I&T; Lutetium (177Lu) zadavotide guraxetan; Lutetium-177 prostate specific membrane antigen I&T; Lutetium-177 PSMA I&T; Lutetium-177 PSMA imaging and therapy

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curium Pharma
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 08 Aug 2025 PDRadiopharma plans a clinical trial in Prostate cancer (Hormone refractory, Metastatic disease) in Japan(IV)
  • 08 Jul 2025 PDRadiopharma files an IND application with the PMDA in Japan for Prostate cancer (Hormone refractory, Metastatic disease)
  • 13 Nov 2024 Curium intends to file a regulatory application for Prostate cancer with the US FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top